Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: Enicepatide, RO7795068, RG6640
CT-388 is a signaling-biased dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR). Published preclinical and clinical research describes cAMP signaling activity at both receptors with minimal receptor internalization. CT-388 has been evaluated in randomized clinical studies involving adults with overweight or obesity, including studies assessing safety, pharmacokinetics, glycemic parameters, and body-weight change.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Phase 1 research evaluated single subcutaneous doses of 0.5–7.5 mg and four once-weekly doses in the 5–12 mg range. A later 48-week Phase 2 study evaluated once-weekly subcutaneous target doses of 4, 8, 12, 16, and 24 mg. These are study regimens reported for research reference only and are not prescribing or administration recommendations.
Supplementary research context only. Not medical advice or a treatment recommendation.
Clinical-trial and development identifiers include CT-388, enicepatide, RO7795068, and RG6640.
ClinicalTrials.gov classifies CT-388 as a synthetic peptide. It remains investigational and is not identified in the cited sources as an approved medicine. Publicly reported clinical data support subcutaneous once-weekly administration in studied protocols.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention CT-388 or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.